Tina J Hieken

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4443890/publications.pdf

Version: 2024-02-01

		172457	161849
123	3,479	29	54
papers	citations	h-index	g-index
126	126	126	4759
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Clinicopathologic models predicting nonâ€sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?. Journal of Surgical Oncology, 2022, 125, 516-524.	1.7	5
2	ASO Visual Abstract: Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma. Annals of Surgical Oncology, 2022, 29, 789-790.	1.5	1
3	Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma. Annals of Surgical Oncology, 2022, 29, 780-786.	1.5	12
4	ASO Author Reflections: Surgeons Adding Valueâ€"Are Synoptic Operative Reports a Step Forward in Cancer Care?. Annals of Surgical Oncology, 2022, , 1.	1.5	1
5	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Annals of Surgical Oncology, 2022, 29, 3694-3708.	1.5	21
6	ASO Visual Abstract: Technical Standards for Cancer Surgeryâ€"Improving Patient Care through Synoptic Operative Reporting. Annals of Surgical Oncology, 2022, , 1.	1.5	0
7	Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study. International Journal of Dermatology, 2022, , .	1.0	4
8	Technical Standards for Cancer Surgery: Improving Patient Care through Synoptic Operative Reporting. Annals of Surgical Oncology, 2022, 29, 6526-6533.	1.5	10
9	Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, 29, 4167-4179.	1.5	1
10	The breast tissue microbiome, stroma, immune cells and breast cancer. Neoplasia, 2022, 27, 100786.	5. 3	9
11	ASO Visual Abstract: Sexual Well-Being After Nipple-Sparing Mastectomy: Does Preservation of the Nipple Matter?. Annals of Surgical Oncology, 2022, , .	1.5	O
12	Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy. Annals of Surgical Oncology, 2022, 29, 5383-5386.	1.5	2
13	Merkel cell carcinoma of unknown primary: Clinical presentation and outcomes. Journal of Surgical Oncology, 2022, 126, 1080-1086.	1.7	4
14	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. Journal of the American College of Surgeons, 2021, 232, 424-431.	0.5	14
15	Contemporary Multi-Institutional Cohort of 550 Cases of Phyllodes Tumors (2007-2017) Demonstrates a Need for More Individualized Margin Guidelines. Journal of Clinical Oncology, 2021, 39, 178-189.	1.6	39
16	Upgrade at excisional biopsy after a core needle biopsy diagnosis of classic lobular carcinoma in situ. Surgery, 2021, 169, 644-648.	1.9	9
17	The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer. Annals of Surgical Oncology, 2021, 28, 2111-2119.	1.5	45
18	Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)., 2021,,.		1

#	Article	IF	Citations
19	Locoregional Management of the Axilla in Mastectomy Patients with One or Two Positive Sentinel Nodes: The Role of Intraoperative Pathology. Clinical Breast Cancer, 2021, 21, 458-465.	2.4	5
20	Active surveillance of patients who have sentinel node positive melanoma: An international, multiâ€institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLTâ€2). Cancer, 2021, 127, 2251-2261.	4.1	37
21	Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. Annals of Surgical Oncology, 2021, 28, 7404-7409.	1.5	9
22	ASO Visual Abstract: Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization. Annals of Surgical Oncology, 2021, 28, 465-466.	1.5	2
23	ASO Author Reflections: Right Sizing Axillary Surgery in Patients treated with Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 8740-8741.	1.5	O
24	Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 8729-8739.	1.5	6
25	ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Annals of Surgical Oncology, 2021, 28, 560-561.	1.5	1
26	Primary tumor resection in patients with stage IV breast cancer: 10â€year experience. Breast Journal, 2021, 27, 863-871.	1.0	3
27	ASO Author Reflections: Adding Value to Multidisciplinary Care by Incorporating Structured Surgeon Survey Assessment of the Effect of Neoadjuvant Therapies on Melanoma Operations. Annals of Surgical Oncology, 2021, 29, 787.	1.5	0
28	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer, 2020, 126, 26-36.	4.1	82
29	Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. European Journal of Cancer, 2020, 140, 11-18.	2.8	31
30	Breast Reconstruction in the Setting of Stage 4 Breast Cancer: Is It Worthwhile?. Annals of Surgical Oncology, 2020, 27, 4730-4739.	1.5	5
31	Reply to E. K. Bartlett et al and A. H. R. Varey et al. JCO Precision Oncology, 2020, 4, 992-994.	3.0	4
32	Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing. Annals of Surgical Oncology, 2020, 27, 3633-3640.	1.5	17
33	Intraoperative Pathologic Margin Analysis and Re-Excision to Minimize Reoperation for Patients Undergoing Breast-Conserving Surgery. Annals of Surgical Oncology, 2020, 27, 5303-5311.	1.5	15
34	Workload Differentiates Breast Surgical Procedures: NSM Associated with Higher Workload Demand than SSM. Annals of Surgical Oncology, 2020, 27, 1318-1326.	1.5	22
35	Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort. Journal of Women's Health, 2020, 29, 1160-1167.	3.3	21
36	Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. British Journal of Surgery, 2020, 107, 1033-1041.	0.3	22

#	Article	IF	CITATIONS
37	Reply to On the proportion of male breast cancer among all breast cancers. Cancer, 2020, 126, 2034-2035.	4.1	1
38	Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. JCO Precision Oncology, 2020, 4, 319-334.	3.0	67
39	Mastectomy and immediate breast reconstruction in the elderly: Trends and outcomes. Surgery, 2019, 166, 709-714.	1.9	30
40	In Reply to Hannoun-Levi and Hannoun. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1177-1179.	0.8	0
41	Outcomes of > 1300 Nipple-Sparing Mastectomies with Immediate Reconstruction: The Impact of Expanding Indications on Complications. Annals of Surgical Oncology, 2019, 26, 3115-3123.	1.5	26
42	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
43	Two-Staged Implant-Based Breast Reconstruction: A Long-Term Outcome Study in a Young Population. Medicina (Lithuania), 2019, 55, 481.	2.0	11
44	Identification of novel, immune-mediating extracellular vesicles in human lymphatic effluent draining primary cutaneous melanoma. Oncolmmunology, 2019, 8, e1667742.	4.6	31
45	Returns to the operating room after breast surgery at a tertiary care medical center. American Journal of Surgery, 2019, 218, 388-392.	1.8	4
46	Patient-reported experience after outpatient breast surgery. American Journal of Surgery, 2019, 218, 175-180.	1.8	5
47	Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen. International Journal of Radiation Oncology Biology Physics, 2019, 104, 75-82.	0.8	27
48	3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen. Radiation Oncology, 2019, 14, 211.	2.7	23
49	Infections following Immediate Implant-Based Breast Reconstruction: A Case-Control Study over 11 Years. Plastic and Reconstructive Surgery, 2019, 144, 1270-1277.	1.4	25
50	Carbon Fiducial Image Guidance Increases the Accuracy of Lumpectomy Cavity Localization in Radiation Therapy for Breast Cancer. Practical Radiation Oncology, 2019, 9, e14-e21.	2.1	3
51	The role of serum lactate dehydrogenase level as a prognostic indicator in resected, high risk melanoma. Dermatologic Therapy, 2019, 32, e12813.	1.7	0
52	The Role of Completion Lymph Node Dissection for Sentinel Lymph Node-Positive Melanoma. Annals of Surgical Oncology, 2019, 26, 1028-1034.	1.5	13
53	Abstract CT121: Neoadjuvant combination targeted and immunotherapy for high-risk resectable stage III melanoma (NeoACTIVATE), NCT03554083. , 2019, , .		2
54	Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience. Breast Cancer Research and Treatment, 2018, 169, 189-196.	2.5	8

#	Article	IF	CITATIONS
55	Durable response of early-stage breast cancer to bilateral definitive SBRT in a medically inoperable patient. Practical Radiation Oncology, 2018, 8, 361-365.	2.1	5
56	Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes. Clinical Breast Cancer, 2018, 18, e501-e506.	2.4	19
57	Neoadjuvant systemic therapy for regionally advanced melanoma. Journal of Surgical Oncology, 2018, 117, 1164-1169.	1.7	12
58	Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology, 2018, 36, 1840-1846.	1.6	22
59	Management of the axilla in metaplastic breast carcinoma. Gland Surgery, 2018, 7, 200-206.	1.1	11
60	A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer and Metastasis Reviews, 2018, 37, 599-614.	5.9	63
61	Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast. Annals of Surgical Oncology, 2018, 25, 3064-3068.	1.5	14
62	Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2018, 25, 2596-2602.	1.5	55
63	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. Npj Breast Cancer, 2018, 4, 26.	5.2	24
64	NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2017, 23, 4055-4065.	7.0	243
65	Mastectomy and Immediate Breast Reconstruction for Cancer in the Elderly: A National Cancer Data Base Study. Journal of the American College of Surgeons, 2017, 224, 895-905.	0.5	26
66	Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer. Clinical Breast Cancer, 2017, 17, e209-e213.	2.4	19
67	Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia. Breast Cancer Research and Treatment, 2017, 164, 295-304.	2.5	68
68	Is axillary surgery beneficial for patients with adenoid cystic carcinoma of the breast?. Journal of Surgical Oncology, 2017, 116, 690-695.	1.7	14
69	Cross-sectional imaging to evaluate the extent of regional nodal disease in breast cancer patients undergoing neoadjuvant systemic therapy. European Journal of Radiology, 2017, 89, 163-168.	2.6	12
70	A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast Cancer. Clinical Cancer Research, 2017, 23, 6823-6832.	7.0	66
71	Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011. Cancer Medicine, 2017, 6, 2203-2212.	2.8	98
72	A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease. Annals of Surgical Oncology, 2017, 24, 2915-2924.	1.5	47

#	Article	IF	Citations
73	Localizing the Clipped Node in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Early Learning Experience and Challenges. Annals of Surgical Oncology, 2017, 24, 3011-3016.	1.5	96
74	Outcomes and feasibility of nipple-sparing mastectomy for node-positive breast cancer Patients. American Journal of Surgery, 2017, 213, 810-813.	1.8	9
75	Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation. Frontiers in Immunology, 2017, 8, 358.	4.8	54
76	Contralateral prophylactic mastectomy and its impact on quality of life. Gland Surgery, 2016, 5, 439-443.	1.1	7
77	A Picture is Worth a Thousand Words: Intraoperative Photography as a Quality Metric for Axillary Dissection. Annals of Surgical Oncology, 2016, 23, 3494-3500.	1.5	3
78	Nipple-Sparing Mastectomy: To Spare Or Not To Spare?. Current Surgery Reports, 2016, 4, 1.	0.9	3
79	Contemporary operative management of T4 breast cancer. Surgery, 2016, 160, 1059-1069.	1.9	8
80	Feasibility and full-course dosimetry of an intraoperatively placed multichannel brachytherapy catheter for accelerated partial breast irradiation. Brachytherapy, 2016, 15, 796-803.	0.5	6
81	Nipple-Sparing Mastectomy: Indications, Contraindications, Risks, Benefits, and Techniques. Annals of Surgical Oncology, 2016, 23, 3138-3144.	1.5	28
82	Contralateral Prophylactic Mastectomy for Women with T4 Locally Advanced Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3365-3370.	1.5	7
83	Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer, 2016, 122, 2971-2978.	4.1	48
84	Frozen section analysis of SLNs in trunk and extremity melanoma has a high false negative rate but can spare some patients a second operation. Journal of Surgical Oncology, 2016, 114, 879-883.	1.7	4
85	The Microbiome of Aseptically Collected Human Breast Tissue in Benign and Malignant Disease. Scientific Reports, 2016, 6, 30751.	3.3	299
86	Clinicopathologic features of breast cancers that develop in women with previous benign breast disease. Cancer, 2016, 122, 378-385.	4.1	31
87	Use of immediate breast reconstruction and choice for contralateral prophylactic mastectomy. Surgery, 2016, 159, 1199-1209.	1.9	39
88	A Novel Treatment Schedule for Rapid Completion of Surgery and Radiation in Early-Stage Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3297-3303.	1.5	12
89	Multiple primary melanoma in the elderly. American Journal of Surgery, 2016, 211, 84-88.	1.8	10
90	Which Breast Cancer Patients WithÂa Positive Sentinel Lymph Node Can Avoid Dissection?. Breast Diseases, 2016, 27, 21-23.	0.0	0

#	Article	IF	Citations
91	Contralateral Prophylactic Mastectomy: Factors Predictive of Occult Malignancy or High-Risk Lesion and the Impact of MRI and Genetic Testing. Annals of Surgical Oncology, 2016, 23, 72-77.	1.5	14
92	Comparative Study of Liposomal Bupivacaine Versus Paravertebral Block for Pain Control Following Mastectomy with Immediate Tissue Expander Reconstruction. Annals of Surgical Oncology, 2016, 23, 465-470.	1.5	25
93	Delineation of factors associated with prolonged length of stay after laparoscopic ventral hernia repair leads to a clinical pathway and improves quality of care. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 1614-1618.	2.4	11
94	Unilateral Arm Urticaria Presenting as a Paraneoplastic Manifestation of Metachronous Bilateral Breast Cancer. Case Reports in Oncology, 2016, 9, 33-38.	0.7	6
95	Axillary Ultrasound in the Management of the Newly Diagnosed Breast Cancer Patient. Breast Journal, 2015, 21, 634-641.	1.0	21
96	Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HERâ€2 positive patients presenting with clinically nodeâ€negative disease. Journal of Surgical Oncology, 2015, 112, 453-457.	1.7	5
97	$\mathrm{ER}\hat{l}^2$ Expression and Breast Cancer Risk Prediction for Women with Atypias. Cancer Prevention Research, 2015, 8, 1084-1092.	1.5	16
98	Radial scar/complex sclerosing lesions: a clinicopathologic correlation study from a single institution. Annals of Diagnostic Pathology, 2015, 19, 24-28.	1.3	37
99	Model for Individualized Prediction of Breast Cancer Risk After a Benign Breast Biopsy. Journal of Clinical Oncology, 2015, 33, 923-929.	1.6	51
100	Increasing Use of Neoadjuvant Treatment for T1 and T2 HER2-Positive Tumors. Annals of Surgical Oncology, 2015, 22, 3369-3375.	1.5	10
101	Frequency of diagnosis of cancer orÂhigh-risk lesion at operation forÂpathologic nipple discharge. Surgery, 2015, 158, 988-995.	1.9	13
102	Expanded Indications and Improved Outcomes for Nipple-Sparing Mastectomy Over Time. Annals of Surgical Oncology, 2015, 22, 3317-3323.	1.5	116
103	Medical factors influencing decision making regarding radiation therapy for breast cancer. International Journal of Women's Health, 2014, 6, 945.	2.6	6
104	Impact of Availability of Immediate Breast Reconstruction on Bilateral Mastectomy Rates for Breast Cancer across the United States: Data from the Nationwide Inpatient Sample. Annals of Surgical Oncology, 2014, 21, 3290-3296.	1.5	40
105	Does BMI Affect the Accuracy of Preoperative Axillary Ultrasound in Breast Cancer Patients?. Annals of Surgical Oncology, 2014, 21, 3278-3283.	1.5	17
106	Surgical Treatment of Borderline and Malignant Phyllodes Tumors: The Effect of the Extent of Resection and Tumor Characteristics on Patient Outcome. Annals of Surgical Oncology, 2014, 21, 3304-3309.	1.5	79
107	Impact of analysis of frozen-section margin on reoperation rates in women undergoing lumpectomy for breast cancer: Evaluation of the National Surgical Quality Improvement Program data. Surgery, 2014, 156, 190-197.	1.9	90
108	Diagnosis and Management of Benign, Atypical, and Indeterminate Breast Lesions Detected on Core Needle Biopsy. Mayo Clinic Proceedings, 2014, 89, 536-547.	3.0	71

#	Article	IF	CITATIONS
109	The Promise of Axillary Imaging in Individualized Surgical Management of Breast Cancer Patients: Another Step Forward. Annals of Surgical Oncology, 2014, 21, 3369-3371.	1.5	11
110	A multivariate model to predict cancer upgrade from atypical ductal hyperplasia by core needle biopsy Journal of Clinical Oncology, 2014, 32, 3-3.	1.6	3
111	Frequency of occult findings in contralateral prophylactic mastectomy as it relates to preoperative MRI or BRCA testing Journal of Clinical Oncology, 2014, 32, 1520-1520.	1.6	0
112	Predicting the biologic classification of phyllodes tumors from preoperative core needle biopsy and imaging findings Journal of Clinical Oncology, 2014, 32, 86-86.	1.6	0
113	Imaging Response and Residual Metastatic Axillary Lymph Node Disease after Neoadjuvant Chemotherapy for Primary Breast Cancer. Annals of Surgical Oncology, 2013, 20, 3199-3204.	1.5	107
114	Management of Benign Intraductal Solitary Papilloma Diagnosed on Core Needle Biopsy. Annals of Surgical Oncology, 2013, 20, 1900-1905.	1.5	94
115	Preoperative axillary imaging with percutaneous lymph node biopsy is valuable in the contemporary management of patients with breast cancer. Surgery, 2013, 154, 831-840.	1.9	89
116	Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes. Melanoma Research, 2013, 23, 132-137.	1.2	24
117	Accuracy of Diagnostic Biopsy for Cutaneous Melanoma: Implications for Surgical Oncologists. International Journal of Surgical Oncology, 2013, 2013, 1-7.	0.6	20
118	Factors Associated with Surgical Decision Making in Women with Early-Stage Breast Cancer: A Literature Review. Journal of Women's Health, 2013, 22, 236-242.	3.3	61
119	Second-look axillary ultrasound after breast MRI for enhanced preoperative nodal staging in newly diagnosed breast cancer patients Journal of Clinical Oncology, 2013, 31, 98-98.	1.6	2
120	Adherence to national quality guidelines for nodal staging and treatment of cutaneous melanoma Journal of Clinical Oncology, 2013, 31, 110-110.	1.6	1
121	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases: commentary on the IBCSG 23-01 Trial. Gland Surgery, 2013, 2, 128-32.	1.1	5
122	Adverse Outcomes Associated with Noncompliance with Melanoma Treatment Guidelines. Annals of Surgical Oncology, 2008, 15, 2395-2402.	1.5	58
123	Contralateral prophylactic mastectomy: a voice for choice. Annals of Breast Surgery, 0, 3, 2-2.	0.8	1